Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Brendan P. Eckelman, Vasily Andrianov et al.|Clinical Cancer Research|2023Cited by 40